Our results identified PTGS2 as an essential mediator implicated in the development of resistance in NSCLC cells exposed to cisplatin, suggesting that PTGS2 might be an effective target for reversal of the acquired resistance. The gene discussed is PTGS2; the disease is non-small cell lung carcinoma.